Cencora (COR) DIvidends Date & History

Key Takeaways

• Cencora, Inc. (COR) pays a quarterly dividend of $0.60 per share, equating to an annualized dividend of $2.40 and a current dividend yield of approximately 0.66% to 0.92%, depending on share price fluctuations.
• The company has raised its dividend for 21 consecutive years, placing it among the more consistent dividend growth names in the healthcare distribution sector.
• Cencora maintains a conservative payout ratio between roughly 18% and 28%, indicating ample earnings coverage and significant room for future dividend increases.
• In November 2025, the Board approved a 9.1% dividend increase from $0.55 to $0.60 per share quarterly, signaling confidence in the company's long-term cash generation.
• The stock is best suited for dividend growth investors who prioritize consistency and long-term compounding over high current income, given its relatively low headline yield.
• Cencora's robust free cash flow of approximately $3.45 billion provides strong backing for its dividend program and share repurchase activities.

Dividend Overview

Cencora, Inc. (COR), formerly known as AmerisourceBergen and rebranded in 2023, is one of the world's largest pharmaceutical distribution and healthcare services companies. The company distributes prescription medicines, over-the-counter (OTC) healthcare products, and home care supplies to a wide network of healthcare providers, including hospitals, pharmacies, and clinics across the United States and internationally.

Cencora pays a quarterly cash dividend of $0.60 per share, which was raised by 9.1% from the prior $0.55 in November 2025. On an annualized basis, the dividend totals $2.40 per share. At recent trading levels, the dividend yield stands between approximately 0.66% and 0.92%, which is modest by broader market standards. Dividends are typically declared in February, May, August, and November, with payment dates following roughly two weeks after each ex-dividend date — the next ex-dividend date is May 15, 2026, with a payment date of June 1, 2026. Cencora is not a high-yield stock; rather, it fits the profile of a steady dividend growth name with a long track record of annual increases.

Dividend History and Growth

Cencora's dividend history tells a story of methodical, uninterrupted growth. According to publicly available dividend records, the company has increased its dividend annually for 21 consecutive years, a streak that places it among the more dependable dividend payers in the healthcare sector. Over the past five fiscal years, the annual dividend per share has grown from $1.76 (fiscal 2021) to $2.20 (fiscal 2025), reflecting a compound annual growth rate (CAGR) in the mid-single digits — approximately 5.3% to 5.8% per year.

The quarterly dividend has risen in measured increments: from $0.44 per share in 2021 to $0.46 in 2022, $0.485 in 2023, $0.51 in 2024, $0.55 in early 2025, and most recently $0.60 in November 2025. Notably, total dividends paid by the company have expanded from approximately $344 million in fiscal 2020 to roughly $437 million in fiscal 2025. This consistent upward trajectory reflects management's disciplined approach to returning capital to shareholders while reinvesting in the core pharmaceutical distribution business.

Dividend Sustainability and Payout Ratio

Cencora's dividend sustainability appears robust. The company's payout ratio, calculated as dividends per share divided by earnings per share (EPS), ranges between approximately 18% and 28% depending on the data source and measurement period. A payout ratio in this range is considered very conservative, especially for a mature healthcare distribution company with predictable cash flows. In the most recent reported quarter (fiscal Q4 2025, ended September 2025), Cencora reported EPS of $3.84, comfortably covering the quarterly dividend of $0.55 at that time.

On a cash flow basis, Cencora generated approximately $3.45 billion in free cash flow during fiscal 2025, providing ample coverage for its roughly $437 million in annual dividend payments. The company's net margin of approximately 0.60% is typical for the pharmaceutical wholesale industry, where revenues are enormous — fiscal 2025 revenue reached approximately $321.33 billion — but margins are thin by design. Despite a fourth-quarter net loss in fiscal 2025 driven by goodwill impairment charges related to the PharmaLex business, the dividend increase announced alongside those results demonstrates management's confidence in underlying cash generation and the long-term health of the enterprise.

Dividend Compared to Industry Peers

Cencora operates in the pharmaceutical distribution sub-industry, where it competes directly with MCK (McKesson Corporation) and CAH (Cardinal Health, Inc.). Together, these three companies dominate U.S. pharmaceutical wholesale distribution. Among this peer group, Cencora's dividend yield of roughly 0.66% to 0.92% sits in the lower-to-middle range. The broader healthcare sector average dividend yield is approximately 1.56%, meaning Cencora's yield appears modest in a wider sector context.

However, a yield-focused comparison alone misses the full picture. Cencora's 21-year dividend growth streak is competitive within its peer group, and its low payout ratio suggests significantly more capacity for future increases compared to some higher-yielding healthcare names. For investors who value dividend reliability and trajectory over current income, Cencora's profile compares favorably within the pharmaceutical distribution space. The company complements its dividend with an active share repurchase program, delivering a combined shareholder yield (dividends plus buybacks) of approximately 1.82%.

AI Screener

For investors looking to identify dividend-paying stocks like Cencora alongside other income and growth opportunities, Tickeron's AI Screener offers a powerful AI-driven stock and ETF discovery platform. The tool enables traders and investors to filter thousands of equities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and AI-generated trading signals. Whether screening for dividend growth stocks, high-yield income plays, breakout candidates, or trending sectors, the AI Screener streamlines the research process and helps surface opportunities that manual screening might miss. Users can tailor searches to match specific investment strategies and market conditions, making it a versatile addition to any research toolkit.

Is This Stock Attractive for Dividend Investors?

Cencora (COR) is most likely to appeal to dividend growth investors and long-term, total-return-oriented shareholders rather than those seeking high current income. With a dividend yield below 1%, the stock does not compete with traditional high-yield sectors such as utilities, real estate investment trusts (REITs), or consumer staples on an income basis. What Cencora offers instead is a durable, 21-year track record of annual dividend increases, a very conservative payout ratio that creates a wide margin of safety, and a business model that generates substantial and relatively predictable free cash flow.

For income-focused investors who need meaningful cash distributions today, Cencora's low yield may be a limiting factor. However, for patient investors building a diversified dividend growth portfolio, the combination of consistent payout hikes, strong cash flow coverage, and a leading position in the essential pharmaceutical supply chain makes Cencora a candidate worth studying. The 9.1% dividend increase announced in late 2025, even amid one-time impairment charges, reinforces the signal that management prioritizes sustained shareholder returns. As always, investors should consider their own financial goals, time horizon, and risk tolerance when evaluating any dividend stock.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations